Enzo Biochem (NYSE:ENZ) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ) in a report published on Saturday. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Performance

ENZ opened at $1.12 on Friday. The firm has a 50-day moving average of $1.12 and a 200 day moving average of $1.13. Enzo Biochem has a fifty-two week low of $0.99 and a fifty-two week high of $1.50.

Hedge Funds Weigh In On Enzo Biochem

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd boosted its position in Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after purchasing an additional 13,735 shares during the period. Renaissance Technologies LLC boosted its position in Enzo Biochem by 2.6% during the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after purchasing an additional 64,417 shares during the period. Finally, Wittenberg Investment Management Inc. bought a new position in Enzo Biochem during the fourth quarter worth about $95,000. Institutional investors own 36.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.